Melanoma & Skin Cancer

Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, discusses long-term outcomes of the CheckMate-204 trial in melanoma.

Georgina V. Long, BSc, PhD, MBBS, FRACP, discusses the long-term data from the phase II ABC study , in which investigators are comparing the efficacy of nivolumab in combination with ipilimumab versus single-agent nivolumab in patients with melanoma brain metastases.

Jeffrey S. Weber, MD, PhD, discusses the rationale behind the randomized, double-blind, phase III CheckMate-238 trial in resected stage III or IV melanoma.

For nearly a decade, immunotherapy and molecularly targeted agents have been the focus of intense development. Now emerging evidence suggests that both modalities can deliver long-term benefits for patients, but the findings may prompt additional questions of how best to fit these transformative therapies into treatment landscapes.

Michael B. Atkins, MD, discusses results from the CA209-004 trial, which was a phase I study analyzing patients with advanced, unresectable melanoma treated with nivolumab plus ipilimumab.

The molecular profile of Merkel cell carcinoma differs depending upon whether the malignancy is driven by ultraviolet light or by a virus and can be correlated with responses to immunotherapy, according to recent study findings.

Jeffrey S. Weber, MD, PhD, discusses the updated analysis of the phase III CheckMate-238 trial in patients with resected stage III/IV melanoma.

The treatment landscape changed significantly with the first melanoma clinical trials in 2001, which evaluated the CTLA-4 antibodies ipilimumab (Yervoy) and tremelimumab.

The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of nivolumab at a flat dosing schedule of either 240 mg over 30 minutes every 2 weeks, or 480 mg infused over 60 minutes every 4 weeks, for the adjuvant treatment of patients with melanoma who have involvement of lymph nodes or metastatic disease who have undergone complete resection.

Keith T. Flaherty, MD, discusses treatment beyond frontline therapy for patients with BRAF-mutant relapsed/refractory melanoma.

Five melanoma experts discuss findings from several exciting studies presented at the 2019 ASCO Annual Meeting that are helping to change the way patients with malignant melanoma are treated.

Paul D. Nathan, MBBS, PhD, FRCP, consultant medical oncologist, Mount Vernon Cancer Centre, discusses the long-term outcomes with the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) in patients with BRAF V600-mutant unresectable or metastatic melanoma.

Mario Sznol, MD, professor of medicine, co-director, Yale SPORE in Skin Cancer, Yale Cancer Center, discusses the benefits of immunotherapy, specifically the combination of the CTLA-4 inhibitoripilimumab and the PD-1 inhibitor nivolumab, in melanoma.